| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Endocrinologia ed Oncologia Molecolare e Clinica, Università Federico II, Via S. Panini, 5, Naples 80131 Italy 1 ASO Ordine Mauriziano di Torino,, Ospedale ‘Umberto I’, Turin, Italy Departments of 2 Scienze Biomorfologiche e Funzionali and 3 Biologia e Patologia Cellulare e Molecolare,, Università Federico II, Naples, Italy 4 Institute of Endocrinologia ed Oncologia Sperimentale ‘G Salvatore’,, Consiglio Nazionale delle Ricerche, Naples, Italy
(Correspondence should be addressed to M Vitale; Email: mavitale{at}unina.it)
Ten to fifteen percent of fine-needle aspiration biopsy (FNAB) of thyroid nodules are indeterminate. Galectin-3 (Gal-3) and the oncogene BRAFV600E are markers of malignancy useful to improve FNAB accuracy. The objective of this study was to determine whether the combined analysis of Gal-3 and BRAFV600E expression in thyroid aspirates could improve the diagnosis in FNAB with suspicious cytological findings. Two hundred and sixty-one surgical thyroid tissues and one hundred and forty-four thyroid aspirates were analyzed for the presence of the two markers. In surgical specimens, Gal-3 expression was present in 27.4% benign nodules, 91.9% papillary (PTC) and 75% follicular (FTC) thyroid carcinomas. BRAFV600E was not detected in 127 benign nodules, as well as in 32 FTCs, while was found in 42.9% PTC. No correlation was found between BRAF mutation and Gal-3 expression. Forty-seven consecutive FNAB suspicious for PTC were analyzed for the presence of the two markers. Of these nodules, 23 were benign at histology, 6 were positive for Gal-3, none displayed BRAFV600E, and 17 were negative for both the markers. Twenty suspicious nodules were diagnosed as PTC and four FTCs at histology. Of these 24 carcinomas, 9 resulted positive for BRAFV600E, 17 for Gal-3, and 22 for one or both the markers. The sensitivity, specificity, and accuracy for the presence of Gal-3 and/or BRAFV600E were significantly higher than those obtained for the two markers alone. Notably, the negative predictive value increased from 70.8 to 89.5%. In conclusion, the combined detection of Gal-3 and BRAFV600E improves the diagnosis in FNAB with cytological findings suspicious for PTC and finds clinical application in selected cases.
This article has been cited by other articles:
|
|
 |
|
  M. C. Zatelli, G. Trasforini, S. Leoni, G. Frigato, M. Buratto, F. Tagliati, R. Rossi, L. Cavazzini, E. Roti, and E. C degli Uberti BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies Eur. J. Endocrinol., September 1, 2009; 161(3): 467 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. E. Nikiforov, D. L. Steward, T. M. Robinson-Smith, B. R. Haugen, J. P. Klopper, Z. Zhu, J. A. Fagin, M. Falciglia, K. Weber, and M. N. Nikiforova Molecular Testing for Mutations in Improving the Fine-Needle Aspiration Diagnosis of Thyroid Nodules J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2092 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Alexander Approach to the Patient with a Cytologically Indeterminate Thyroid Nodule J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4175 - 4182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eszlinger, K. Krohn, S. Hauptmann, H. Dralle, T. J. Giordano, and R. Paschke Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3286 - 3294. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
